BioCentury
ARTICLE | Finance

Prexton's PD inflection

What Merck Serono spinout Prexton plans to do with fresh €8.7M A round

March 2, 2015 8:00 AM UTC

Prexton Therapeutics S.A. became the first spinout from Merck Serono S.A.'s Entrepreneur Partnership Program to raise follow-on funding with the close of its €8.7 million ($9.9 million) series A round last week. The cash will enable the biotech to complete a Phase I trial of its lead small molecule, a positive allosteric modulator (PAM) of mGluR4, which is in development to alleviate Parkinson's disease symptoms.

New investors Sunstone Capital and Ysios Capital co-led the round. Existing investor MS Ventures also participated. ...